Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $2.14M invested in Proshares UltraPro NASDAQ Biotechnology in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
233% more call options, than puts
Call options by funds: $2.85M | Put options by funds: $856K
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
33% less capital invested
Capital invested by funds: $3.18M → $2.14M (-$1.04M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$561K |
| 2 |
Jane Street
New York
|
+$258K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$47.4K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$2.22M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$547K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$212K |
| 4 |
Morgan Stanley
New York
|
-$5.7K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$142 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $641K | +$258K | +9,052 | +69% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $569K | +$561K | +19,693 | New |
|
|
VF
3
Virtu Financial
New York
| $429K | -$2.22M | -77,824 | -84% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $396K | -$547K | -19,208 | -58% |
|
|
5
UBS Group
Zurich,
Switzerland
| $76K | +$47.4K | +1,666 | +174% |
|
|
6
Simplex Trading
Chicago,
Illinois
| $18K | +$18.1K | +637 | New |
|
|
7
Morgan Stanley
New York
| $11K | -$5.7K | -200 | -34% |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$212K | -9,976 | Closed |
|
|
CG
9
Cutler Group
San Francisco,
California
| – | -$142 | -5 | Closed |
|
UBIO Hedge Fund Activity: Q3 2016 in Review
7 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q3 2016, worth a combined $2.14M — down 33% from $3.18M a quarter earlier.
Fund positioning in UBIO was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $561K. The largest seller was Virtu Financial, cutting an estimated $2.22M.
- 7 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $2.14M of Proshares UltraPro NASDAQ Biotechnology stock for Q3 2016, down 33% quarter-over-quarter.
- 2 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q3 2016 was Susquehanna International Group, an estimated $561K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q3 2016 was Virtu Financial, an estimated $2.22M sold.
Based on aggregated 13F filings for Q3 2016.